Cite
HARVARD Citation
Yardley, D. et al. (2015). Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 16 (1), pp. 1-10. [Online].